- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02212652
Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes (VISTA)
The Effect of VItamin D Supplementation on Nutritional STatus and Adverse Outcomes in Bariatric Surgery (VISTA)
VISTA is looking to see if vitamin D supplements before bariatric surgery might improve vitamin D stores, which may help to prevent some complications like infections.
Who can join this research study?
- Approved to undergo bariatric surgery-Roux-en-Y Gastric Bypass or Vertical Sleeve Gastrectomy-at the Johns Hopkins Bayview Medical Center
- 18 to 64 years of age
- BMI of 35 to 49.9 kg/m2
- VitD insufficient or deficient prior to having surgery
What will happen if a participant chooses to participate in this research study?
- The participant will be randomly assigned (by chance) to receive either:
- Standard care plus vitamin D supplements or
- Standard care plus a placebo (contains no vitamin D)
- Either would be provided at no cost to the participant
- The investigators will ask the participant to complete a survey on the day of surgery regarding supplement use
- The investigators will follow the participants medical record through the 12 month follow up clinic visit.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
An estimated 2 in 3 American adults are either overweight (BMI 25-29.9 kg/m2) or obese (BMI 30-39.9 kg/m2). The prevalence of obesity, morbid obesity (BMI 40-44.9 kg/m2), and even super obesity (BMI ≥ 45 kg/m2) are increasing. Obesity is a leading contributor to global mortality and contributes to the burden of disease associated with diabetes, cardiovascular disease, musculoskeletal disorders such as osteoarthritis, and some cancers. Morbid obesity reduces life expectancy by 8 to 10 years, similar to the effect of being a regular cigarette smoker.
Several studies have demonstrated that most obese adults are vitamin D (VitD) insufficient (<75 nmol/L, 30 ng/ml) or deficient (<50 nmol/L, 20 ng/ml). The inverse relationship between body mass index (BMI) or body fat mass and VitD status is hypothesized to be due to sequestration of VitD by adipose tissue, reducing the bioavailability of VitD. The classical role of VitD is in the maintenance of bone calcification, but more recent research has elucidated a more varied role for this hormone. Lack of VitD has been associated with increased susceptibility to infection, autoimmunity, cancer, and chronic disease.
Bariatric surgery is currently the most successful means of long-term weight loss. Since deficiency in fat-soluble vitamins, such as VitD, is considered a metabolic complication of bariatric surgery, determining the VitD status of these individuals and perhaps correcting it prior to surgery may prove greatly beneficial. Potential complications relating to VitD insufficiency and deficiency include adverse surgical outcomes such as improper wound healing, infection of the surgical incision, and atrial fibrillation. Since the indications for bariatric surgery are obesity and obesity-related comorbidities, bariatric surgery patients are at an increased risk of having an adverse surgical outcome.
The Johns Hopkins Center for Bariatric Surgery (JHCBS) is designated as a Center of Excellence by the American College of Surgeons. To comply with this designation, the center must maintain a certain standard of care (SoC) and minimize complication rates. Given the potential relationship between VitD status and adverse surgical outcomes, the investigators are currently reviewing pre-operative VitD status (serum 25(OH)D concentration) collected as routine SoC and investigating the relationship with surgical outcomes under an Institutional Review Board (IRB) approved protocol (NA_00087502). The investigators findings reveal that most of bariatric surgery patients are VitD insufficient and deficient pre-operatively. To date, there is no standard regarding treating these deficiencies pre-operatively and as such the center does not intervene prior to surgery. A randomized, double-blinded, placebo-controlled pilot trial is needed to assess the causality of the relationship between pre-operative VitD status and adverse surgical outcomes in the bariatric surgical patient.
The investigators plan to identify new patients approved for bariatric surgery at the JHCBS. These patients will be randomized consecutively in a 1:1 ratio to either 30 days of 10,000 International Units (IU) of VitD3 plus SoC or 30 days of placebo plus SoC immediately prior to surgery. The investigators will monitor these patients for any adverse surgical outcomes, including wound infection, dehiscence, and prolonged length of hospital stay. The investigators will also monitor their long-term clinical outcomes such as malnutrition, weight loss, and resolution of comorbidities at their routine clinic care visit: 2 weeks, 6 weeks, 3 months, 6 months, and 12 months post-operatively. At these visits the patients are assessed for wound healing, weight loss, nutritional status, and other key markers of health, such as vital signs.
The investigators aim to determine if 10,000 IU of VitD3 daily for 30 days prior to bariatric surgery (Roux-en Y Gastric Bypass (RYGB) or Vertical Sleeve Gastrectomy (VSG)) will significantly increase the VitD status (serum 25(OH)D concentration) and whether the associated change in VitD status leads to decrease risk of adverse surgical outcomes and/or improved clinical outcomes.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- The Johns Hopkins Center for Bariatric Surgery
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients approved for and undergoing clinically indicated bariatric surgery -Roux-en-Y Gastric Bypass (RYGBP) or Vertical Sleeve Gastrectomy (VSG)
- 18 to 64 years of age
- BMI of 35 to 49.9 kg/m2
- VitD insufficient pre-operatively: serum 25(OH)D concentration < 75 nmol/L or 30 ng/ml
Exclusion Criteria:
- Any patient who does not want to participate in the study
- Any patient who has dietary restrictions/proscriptions prohibiting ingestion of beef gelatin
- Expected poor compliance with the medical regimen
- Any active medical conditions that could, in the opinion of the investigators, jeopardize the safety of the subject or the integrity of the study
- The elective bariatric surgery is cancelled prior to incision by a surgeon for any reason
- Pregnancy: The routine standard of care is to determine whether a female patient is pregnant either by history and/or urinary pregnancy test on the day of surgery. No additional testing specifically for this study is planned beyond the standard of care.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Standard of Care plus Vitamin D
If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care.
We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
|
10,000 IU of VitD3 daily (one gel daily)
Otros nombres:
Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
|
Comparador de placebos: Standard of Care plus Placebo
If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care.
We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
|
Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
Gummy button placebo, which will appear very similar to the vitamin D supplement.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Vitamin D status as measured by serum 25(OH)D concentration.
Periodo de tiempo: Up to 12 months after surgery
|
Improved post-operative vitamin D status as measured by serum 25(OH)D concentration.
|
Up to 12 months after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Adverse surgical outcomes (aggregate)
Periodo de tiempo: Up to 30 days after surgery
|
Adverse surgical outcomes include surgical site infection, wound separation and dehiscence, anastomotic leak, prolonged length of hospital stay (> 3 days), and re-admittance to the hospital within 30 days post-operatively.
|
Up to 30 days after surgery
|
Clinical outcomes (aggregate)
Periodo de tiempo: Up to 12 months after surgery
|
Long-term clinical outcomes include wound healing, weight loss, nutritional status, resolution of comorbidities, and other key markers of health, such as vital signs (fever, blood pressure, heart rate, pain, etc.) and return of a regular menstrual cycle.
|
Up to 12 months after surgery
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kimberley E Steele, MD, PhD, Johns Hopkins University
- Director de estudio: Michael A. Schweitzer, MD, Johns Hopkins University
- Director de estudio: Thomas H Magnuson, MD, Johns Hopkins University
Publicaciones y enlaces útiles
Publicaciones Generales
- Quraishi SA, Bittner EA, Blum L, Hutter MM, Camargo CA Jr. Association between preoperative 25-hydroxyvitamin D level and hospital-acquired infections following Roux-en-Y gastric bypass surgery. JAMA Surg. 2014 Feb;149(2):112-8. doi: 10.1001/jamasurg.2013.3176.
- Goldner WS, Stoner JA, Lyden E, Thompson J, Taylor K, Larson L, Erickson J, McBride C. Finding the optimal dose of vitamin D following Roux-en-Y gastric bypass: a prospective, randomized pilot clinical trial. Obes Surg. 2009 Feb;19(2):173-179. doi: 10.1007/s11695-008-9680-y. Epub 2008 Sep 16.
- Lin E, Armstrong-Moore D, Liang Z, Sweeney JF, Torres WE, Ziegler TR, Tangpricha V, Gletsu-Miller N. Contribution of adipose tissue to plasma 25-hydroxyvitamin D concentrations during weight loss following gastric bypass surgery. Obesity (Silver Spring). 2011 Mar;19(3):588-94. doi: 10.1038/oby.2010.239. Epub 2010 Oct 14.
- Nguyen S, Baggerly L, French C, Heaney RP, Gorham ED, Garland CF. 25-Hydroxyvitamin D in the range of 20 to 100 ng/mL and incidence of kidney stones. Am J Public Health. 2014 Sep;104(9):1783-7. doi: 10.2105/AJPH.2013.301368. Epub 2013 Oct 17.
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB00044789
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Deficiencia de vitamina D
-
University of UlsterDairy Council for Northern Ireland; Agri-food & Biosciences Institute; Center for...TerminadoConcentración de 25-hidroxivitamina D (estado de vitamina D)Reino Unido
-
University of UlsterNorthern Ireland Executive; HSC Public Health AgencyTerminadoEstado de la vitamina D | Concentración de vitamina DReino Unido
-
Azienda Ospedaliera di BolzanoTerminadoMedición de 25(OH)D y deficiencia de 25(OH)D
-
University College CorkTerminadoEstado de la vitamina D reflejado por la 25-hidroxivitamina D séricaIrlanda
-
University of Eastern FinlandTerminadoExpresión del gen diana del receptor de vitamina D | Concentración sérica de 25(OH)DFinlandia
-
Eiger BioPharmaceuticalsTerminado
-
Hospices Civils de LyonTerminado
-
Horopito LimitedAtlantia Food Clinical TrialsTerminado
-
University of Eastern FinlandDSM Nutritional Products, Inc.TerminadoExpresión del gen diana del receptor de vitamina D | Concentración sérica de 25(OH)DFinlandia
-
Eiger BioPharmaceuticalsAnkara UniversityTerminadoInfección crónica por hepatitis DPavo
Ensayos clínicos sobre Vitamin D
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkTerminadoMigraña según los criterios de la International Headache Society (IHS) (ICHD-II)Dinamarca
-
Royal Prince Alfred Hospital, Sydney, AustraliaTerminadoColonoscopiaAustralia
-
Rhode Island HospitalVirtually Better, Inc.TerminadoSalud mental | Virus de inmunodeficiencia humanaEstados Unidos
-
GlaxoSmithKlineTerminadoInfluenza HumanaEstados Unidos, Bélgica
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Aún no reclutando
-
University Medical Center GroningenMaastricht University Medical Center; UMC Utrecht; Academisch Medisch Centrum -... y otros colaboradoresTerminadoInsuficiencia cardiacaPaíses Bajos
-
Daewoong Pharmaceutical Co. LTD.Aún no reclutando
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; AP Moeller Foundation; Danish Diabetes...ReclutamientoEnvejecimiento | Trastorno del metabolismo | Cetonemia | Trastorno muscularDinamarca
-
Heartseed Inc.ReclutamientoInsuficiencia cardiaca | Enfermedad isquémica del corazónJapón
-
Abbott Medical DevicesTerminadoInsuficiencia cardiacaEstados Unidos